文献速递静脉血栓栓塞

COVID-19患者静脉血栓栓塞症的风险与管理

Risk and Management of Venous Thromboembolism in Patients with COVID-19.
PubMed 文献 · Ann Vasc Surg · 2021-02-10

本文综述了COVID-19患者静脉血栓栓塞症(VTE)的风险与管理,并总结了学会指南及本中心实践路径。尽管COVID-19患者VTE风险显著,但缺乏最佳 mitigating 策略的文献,学会指南指导有限。建议疑似或确诊COVID-19住院患者若出血风险可接受则接受药物预防;急诊或出院患者若出血风险低可延长血栓预防至39天。

要点

  • COVID-19患者VTE风险显著,但缺乏最佳预防和管理证据。
  • 住院疑似或确诊COVID-19患者,出血风险可接受时建议药物预防。
  • 急诊或出院COVID-19患者,出血风险低时建议延长血栓预防至39天。

核心结论

  • COVID-19患者VTE风险显著,但现有文献和学会指南对预防与管理指导有限,需更多研究标准化方案。

研究设计与样本

  • 文献综述,总结COVID-19患者VTE并发症的文献、学会指南及本中心住院和门诊VTE管理路径。

主要发现

  • COVID-19患者VTE风险显著已被确认,但缺乏关于最佳缓解风险的文献。
  • 学会指南对COVID-19相关VTE的预防和管理指导非常有限。

关键数值与推荐

  • 疑似或确诊COVID-19住院患者,若出血风险可接受,建议接受药物预防。
  • COVID-19患者从急诊或医院出院后,若出血风险低,建议延长血栓预防至39天。

临床怎么用

  • 对住院COVID-19患者评估出血风险,可接受时给予药物血栓预防。
  • 对出院COVID-19患者评估出血风险,低风险者考虑延长血栓预防至39天。

局限性

  • 文献缺乏关于最佳缓解VTE风险的证据,学会指南指导有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the most pronounced and poorly understood pathological features of COVID-19 infection has been high risk for venous and arterial thromboembolic complications. An increasing number of thromboembolic events are being reported almost on a daily basis, and the medical community has struggled to predict and mitigate this risk. We aimed to review available literature on the risk and management of COVID-19 related venous thromboembolism (VTE), and provide evidence-based guidance to manage these events. METHODS: A literature review of VTE complications in patients with COVID-19 was performed, in addition to a summary of the societal guidelines and present pathways implemented at our institution for the management of both in- and outpatient COVID-19 related VTE. RESULTS: Although a significant VTE risk has been confirmed in patients with COVID-19, literature addressing best ways to mitigate this risk is lacking. Furthermore, there has been very limited guidance provided by societal guidelines to help prevent and manage VTE associated with the COVID-19 infection. In light of the available data, we advise that all patients admitted with suspected or confirmed COVID-19 receive pharmacological prophylaxis if bleeding risk is acceptable. For patients with COVID-19 who have been discharged from the emergency department or hospital, we suggest extended thromboprophylaxis (up to 39 days) as long as bleeding risk is low. CONCLUSIONS: We believe that this literature summary along with our center recommendations and algorithms provide valuable guidance to providers caring for patients with COVID-19 related VTE. More research is needed to standardize prophylaxis and management protocols for these patients.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Skeik N, Smith JE, Patel L, et al. Risk and Management of Venous Thromboembolism in Patients with COVID-19. Ann Vasc Surg. 2021. PMID: 33333197. doi:10.1016/j.avsg.2020.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。